Vor Biopharma Inc. Increase Decrease In Operating Lease Liability
Vor Biopharma Inc. (VOR) reported Increase Decrease In Operating Lease Liability of -$123.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Vor Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$62.00K.
- Vor Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$61.00K.
- Vor Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$59.00K.
- Vor Biopharma Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$20.00K.
- Vor Biopharma Inc. increase decrease in operating lease liability for fiscal 2025 was -$2.41M.
- Vor Biopharma Inc. increase decrease in operating lease liability for fiscal 2024 was -$3.83M.
- Vor Biopharma Inc. increase decrease in operating lease liability for fiscal 2023 was -$3.58M.
- Vor Biopharma Inc. increase decrease in operating lease liability for fiscal 2022 was -$10.45M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 3 month as first filed | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$123.00K 10-Q · filed 2026-08-11 | -$182.00K derived: sum of 3 quarters · filed 2026-08-11 | -$202.00K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$61.00K 10-Q · filed 2026-05-13 | -$120.00K derived: sum of 2 quarters · filed 2026-05-13 | -$140.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.42M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$79.00K derived: sum of 2 quarters · filed 2026-03-30 | -$1.36M derived: sum of 3 quarters · filed 2026-08-11 | -$2.41M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.30M derived: sum of 2 quarters · filed 2026-08-11 | -$2.35M 10-Q · filed 2025-11-13 | -$3.37M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.33M 10-Q · filed 2026-08-11 | -$3.35M derived: sum of 3 quarters · filed 2026-08-11 | -$4.32M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$1.05M 10-Q · filed 2026-05-13 | -$2.07M derived: sum of 2 quarters · filed 2026-05-13 | -$3.04M derived: sum of 3 quarters · filed 2026-05-13 | -$3.96M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.99M derived: sum of 2 quarters · filed 2026-03-30 | -$2.91M derived: sum of 3 quarters · filed 2026-03-30 | -$3.83M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | -$966.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.89M derived: sum of 2 quarters · filed 2025-11-13 | -$2.81M 10-Q · filed 2025-11-13 | -$3.74M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$919.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.84M 10-Q · filed 2025-08-12 | -$2.78M derived: sum of 3 quarters · filed 2025-08-12 | -$3.69M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$921.00K 10-Q · filed 2025-05-14 | -$1.86M derived: sum of 2 quarters · filed 2025-05-14 | -$2.77M derived: sum of 3 quarters · filed 2025-05-14 | -$3.77M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$1.85M derived: sum of 2 quarters · filed 2025-03-20 | -$2.85M derived: sum of 3 quarters · filed 2025-03-20 | -$3.58M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$917.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.92M derived: sum of 2 quarters · filed 2024-11-07 | -$2.65M 10-Q · filed 2024-11-07 | -$4.06M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$999.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.73M 10-Q · filed 2024-08-08 | -$3.15M derived: sum of 3 quarters · filed 2024-08-08 | -$5.15M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$730.00K 10-Q · filed 2024-05-09 | -$1.54M 10-Q · filed 2023-05-11 | -$2.15M derived: sum of 2 quarters · filed 2024-05-09 | -$4.15M derived: sum of 3 quarters · filed 2024-05-09 | -$10.46M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$3.42M derived: sum of 2 quarters · filed 2024-03-20 | -$9.73M derived: sum of 3 quarters · filed 2024-03-20 | -$10.45M 10-K · filed 2024-03-20 | -$13.31M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$8.31M derived: sum of 2 quarters · filed 2023-11-07 | -$9.04M 10-Q · filed 2023-11-07 | -$10.59M 10-Q · filed 2022-11-10 | -$9.76M derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | -$6.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$7.04M 10-Q · filed 2023-08-10 | -$8.24M 10-Q · filed 2022-08-11 | -$7.76M derived: sum of 3 quarters · filed 2023-08-10 | -$8.46M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$727.00K 10-Q · filed 2023-05-11 | -$1.45M derived: sum of 2 quarters · filed 2023-05-11 | -$2.15M derived: sum of 3 quarters · filed 2023-05-11 | -$3.27M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$719.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$1.42M derived: sum of 2 quarters · filed 2023-03-23 | -$2.54M derived: sum of 3 quarters · filed 2023-03-23 | -$2.56M 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | -$699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.82M derived: sum of 2 quarters · filed 2022-11-10 | -$1.84M 10-Q · filed 2022-11-10 | -$1.99M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.14M 10-Q · filed 2022-08-11 | -$1.29M derived: sum of 3 quarters · filed 2022-08-11 | |||||
| 2021-03-31 | -$16.00K 10-Q · filed 2022-05-12 | -$168.00K derived: sum of 2 quarters · filed 2022-05-12 | ||||||
| 2020-12-31 | -$152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $393.00K 10-K · filed 2022-03-14 | ||||||
| 2020-09-30 | $545.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |